INTRAUTERINE DEVICES AND INFECTIONS. Tips for Evaluation and Management

Similar documents
Gynaecology. Pelvic inflammatory disesase

Stephanie. STD Diagnosis and Treatment. STD Screening for Women. Physical Exam. Cervix with discharge from os

PELVIC INFLAMMATORY DISEASE (PID)

2

MANAGEMENT OF ACUTE PELVIC INFLAMMATORY DISEASE

Sexually Transmitted Infections: New Tests, New Guidelines

Acute Salpingitis. Fallopian Tubes. Uterus

Syphilis: Screening (USPSFT) Syphilis: Screening. Sexually Transmitted Diseases. Family Medicine Board Review Course. Reference

Categories of STI Screening and Testing Routine screening Population based risk factors Targeted screening Personal behavioral risk factors Contact te

STI Indicators by STI

Pelvic Inflammatory Disease

Sexually Transmitted Diseases. Summary of CDC Treatment Guidelines

Gonococcal Infection- Treatment Consideration

CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION 6. Friday, MARCH 18, 2016 STUDENT COPY

9. Sorting out pelvic inflammatory disease

CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI. Friday, MARCH 20, 2015 STUDENT COPY

Bursting Pelvic Inflammatory Disease.

Intrauterine Devices and Pelvic Inflammatory Disease: Dispelling the Myth. Dr Amy Moten SHine SA Co-authors: Dr Richelle Douglas; Dr Alison Creagh SHQ

which may be secondary to associated cervicitis and endometritis.

Pelvic Inflammatory Disease (PID) Max Brinsmead PhD FRANZCOG July 2011

X-Treme Primary Care: HPV and STIs. Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers

Richmond, Virginia. I ve have this terrible pain

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

Bursting Pelvic Inflammatory Disease.

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations

8/20/18. Objectives. STI Presentations. Chlamydia Gonorrhea. Herpes Simples Virus

Answers to those burning questions -

The (likely) New 2010 CDC STD Treatment Guidelines Guideline Development Process. Overview

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

CLINICAL MANAGEMENT OF STDS

Drugs for UTIs and STDs. Dr.Vishaal Bhat Associate Professor MMMC Manipal

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use

25/02/2016. New onset low abdominal pain in women of reproductive age. New onset low abdominal pain: why it matters?

Instruction for the patient

SEXUALLY TRANSMITTED DISEASES TREATMENT GUIDELINES (Part 1 of 5)

Disclosures. STD Screening for Women. Chlamydia & Gonorrhea. I have no disclosures or conflicts of interest to report.

Medical Eligibility for Contraception Use

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

Chlamydia Curriculum. Chlamydia. Chlamydia trachomatis

20. VAGINITIS AND SEXUALLY TRANSMITTED DISEASES 5. Allison L. Diamant, MD, MSPH, and Eve Kerr, MD, MPH

Welcome to: Coding Scenarios for STD Clinic Visits. We will begin in a few minutes. There will be no sound until the webinar starts.

A Prospective Study Of Comparison Of Efficacy Of Two Combination Treatment Regimens In Syndromic Treatment Of Pelvic Inflammatory Disease

Dr. Russo reports no financial relationships relevant to this article. Dr Creinin is a senior clinical advisor for Medicines360.

Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham

Pelvic inflammatory disease An approach for GPs in Australia

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common

Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313

Sexually Transmitted Diseases

Best Practices in STD Partner Management

NCC Pediatrics Continuity Clinic Curriculum: Adolescent Addendum: STDs Faculty Guide

2

Alberta Treatment Guidelines for Sexually Transmitted Infections (STI) in Adolescents and Adults 2008

5/12/11. STI s in Adolescents: Exposing the Hidden Epidemic. Why the hidden epidemic?

Learning Objectives VAGINITIS. Normal Vaginal Discharge. Learning Objectives

NCC Pediatrics Continuity Clinic Curriculum: Adolescent: STIs

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?

No endogenous bacterial contamination Vagina entered. Clean-contaminated. Clean. Contaminated

Review on the outpatient treatment for pelvic inflammatory disease, what is the best for Hong Kong?

NCC Pediatrics Continuity Clinic Curriculum: Adolescent: STIs Faculty Guide

The objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and

Review Article Treatment of Acute Pelvic Inflammatory Disease

Genital Tract Infections in Women. Michael S. Policar, MD, MPH UCSF School of Medicine

Clinical Cases from the STD Clinical Consultation Network

1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.

Novos desafios para controlar as infecções sexualmente transmissíveis [New Challenges in Managing Sexually Transmitted Infections]

New Guidelines for Detection and Treatment of Sexually Transmitted Infections

THE EFFECTIVENESS FOR TREATMENT OF PELVIC INFLAMMATORY DISEASE ON LONG-TERM SEQUELAE. Gail Trautmann. MA, Ball State University, 2001

GONORRHEA; ACUTE Does Not Include Chronic Gonorrhea

S403- Update on STIs for the Generalists

EHIVQUAL. For use with ehivqual, an electronic web based program for quality of care data collection and review REVIEW PERIOD:

VCHIP LARC Needs Assessment Survey

Sexually Transmitted Disease Treatment Tables

PID and Pelvic TB Ina S. Irabon, MD, FPOGS, FPSRM, FPSGE

Chlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University

What Bugs You? A Sexually Transmitted Infection Review

Contributors: Reviewers: Graphic Designer:

STI Treatment Guidelines. Teodora Wi. Training Course in Sexual and Reproductive Health Research

Example Clinical Guideline for Immediate Postpartum LARC Insertion

Index. Infect Dis Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

Sexually transmitted infections (in women)

Immediate Postpartum Long-Term Reversible Contraception (LARC) Bethany Berry, CNM, MSN and Alyssa Givens, MSN, RN

Timby/Smith: Introductory Medical-Surgical Nursing, 9/e

Nothing to disclose.

Levonorgestrel Intrauterine Device

GUIDELINES FOR THE MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS

Abdominal pain for evaluation. Dr Sanket Sontakke (DNB paediatrics 1st yr, Apollo children s hospital) GUIDE: Dr Shyamala J

Update on Sexual Health: Screening, Diagnosing and Treating STIs

STIs- REVISION. Prof A A Hoosen

Clinical Study Tuboovarian Abscesses: Is Size Associated with Duration of Hospitalization & Complications?

ACCESS LARC INCREASING ACCESS TO IMMEDIATE POSTPARTUM LONG-ACTING REVERSIBLE CONTRACEPTION

WHAT ARE CONTRACEPTIVES?

TO DECREASE THE CHANCE OF GETTING

- Polyurethane condoms comparable to latex. - Natural (i.e. Lamb Skin) - Pores 10x > diameter of HIV virus; 25x > diameter Hep B

LIVE PLACEMENT TRAINING WEBCAST

10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE GOAL

HOT OFF THE PRESS! R.

Expanding Access to Birth Control: Will Women Get the Care They Need?

Chronic Pelvic Pain. AP099, December 2010

SEXUALLY TRANSMITTED INFECTIONS IN ST LOUIS

Transcription:

INTRAUTERINE DEVICES AND INFECTIONS Tips for Evaluation and Management

Objectives At the end of this presentation, the participant should be able to: 1. Diagnose infection after IUD placement 2. Provide recommendations for management of pelvic inflammatory disease after placement of IUD

IUDs do not increase risk of PID In the 1970 s the Dalkon shield was associated with increase risk of PID and septic abortion cause: design flaw porous, multifilament string on which bacteria could travel Modern IUDs Use monofilament strings Excellent safety record Lee NC, et al. Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol 1983;62:1-6. Meirik O. Intrauterine devices upper and lower genital tract infections. Contraception 2007;75:S41-47.

Can we prevent infection at time of IUD insertion?

Risks of infection Greatest risk in the first 20 days after IUD insertion Risk does not increase with prolonged use When counseling and reviewing instructions, always reinforce the use of condoms for STI prevention Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785 8. Grimes DA, Lopez LM, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database of Systematic Reviews 1999, Issue 3. Caddy S, et al. Best practices to minimize risk of infection with intrauterine device insertion. JOGC 2014;36(3):266-274.

Reducing Risk of Infection Patient selection, avoid IUD insertion if: Current PID Purulent cervicitis Current known gonorrhea or chlamydia infection Peri-partum chorioamnionitis, endometritis or postpartum sepsis Immediate post-septic abortion Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65. IMAP statement on intrauterine devices. International Medical Advisory Panel. IPPF Med Bull 2003;37(2):1 4.

Screening for STI at the time of IUD insertion Most women do not require additional STI screening at the time of IUD insertion, if they have already been screened according to guidelines If a woman with risk factors for STIs has not been screened, screening can be performed at the time of IUD insertion IUD insertion should not be delayed

At the time of IUD insertion All women should be screened with history and physical exam Sexual history Pelvic exam Assess for CMT during bimanual exam If purulent discharge seen test for infection prior placement and do not place the IUD Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65.

STI Screening and IUD insertion Screen high risk women for STIs <25 years old New sexual partner >1 partner in last year Prior history of STI within the past year Sex partner who has an STI or has other partners You do not need to wait for the results before IUD insertion Sufrin CB, et al. Neisseria gonorrhea and Chlamydia tracomatis screening at Intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012 Dec;120(6):1314-21. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines 2015

Reducing Risk of Infection Procedure No touch technique Cleanse cervix Use sterilized equipment Avoid contamination of the device Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65.

Reducing Risk of PID Do not routinely screen for BV or treat asymptomatic infection Do not routinely use antibiotic prophylaxis Caddy S, et al. Best practices to minimize risk of infection with intrauterine device insertion. JOGC 2014;36(3):266-274.

A word about special populations Adolescents MEC category 2 Generally can use concerns for risk for expulsion in nulliparous women and for STD from sexual behavior HIV-positive women Clinically well and receiving ARV therapy MEC category 1 Can use Not clinically well or not receiving ARV MEC category 2 (initiation) Generally can use MEC category 1 (continuation) Can use Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65.

How do we diagnose and treat PID after IUD insertion?

Causes of PID Caused by polymicrobial infection Other risk factors: Cervicitis (gonorrhea or chlamydia) Poor handling of IUD / contamination Bacterial vaginosis Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Diagnosis of PID Pelvic or lower abdominal pain, and one or more of: Cervical motion tenderness Uterine tenderness Adnexal tenderness Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Diagnosis of PID Enhancing specificity of diagnosis: Oral temperature > 101 F (>38.3 C) Abnormal cervical mucopurulent discharge* or cervical friability Abundant WBCs on saline microscopy of vaginal fluid Elevated erythrocyte sedimentation rate Elevated C-reactive protein Positive chlamydia and gonorrhea testing Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

PID after IUD - Management The IUD does NOT need to be removed. Test for STIs (if not tested at the time of IUD insertion) Condom use counseling Initiate therapy Reassess the woman in 48-72 hours If no clinical improvement occurs, continue antibiotics and consider removal of the IUD Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

PID after IUD insertion If the woman wants to discontinue IUD, Remove the IUD sometime after antibiotics have been started (avoid the potential risk for bacterial spread resulting from the removal procedure) If the IUD is removed, Consider Emergency Contraception Counsel on alternative contraceptive methods Insert Nexplanon, inject Depo Provera or start OC/Ring/Patch Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65.

Management of PID after IUD Outpatient treatment Recommended intramuscular and oral regimens Ceftriaxone 250 mg IM single dose Plus Doxycycline 100 mg orally BID x 14days With or Without Metronidazole 500 mg orally BID x 14 days Cefoxitin 2 gm IM single dose Plus Doxycycline 100 mg orally BID x 14 days With or without Metronidazole 500 mg orally BID x 14 days Other parenteral 3 rd generation cephalosporin (ceftizoxime or cefotaxime) 2015 CDC STD Treatment Guidelines Plus Doxycycline 100 mg orally BID x 14 days With or without Metronidazole 500 mg orally BID x 14 days

PID after IUD Follow-up Re-asses in 72 hours If clinically improving Reinforce to complete regimen Reinforce condoms use for STI prevention If no improvement Hospitalization Assessment of antibiotic regimen Additional diagnostics Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Management of PID after IUD Criteria for inpatient treatment: Surgical emergencies cannot be excluded No clinical response after 72 hours of tx Unable to tolerate outpatient regimen Severe illness, nausea, vomiting or high fever Tubo-ovarian abscess Pregnancy Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Management of PID after IUD Inpatient treatment Recommended parenteral regimens Cefotetan 2 g IV q 12 hours Plus Doxycycline 100 mg orally or IV q 12 hours Cefoxitin 2 g IV q 6 hours Clindamycin 900 mg IV q 8 hours Plus Doxycycline 100 mg orally or IV q 12 hours Plus Gentamicin IV or IM loading dose (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) q 8 hours Single daily dosing (3-5 mg/kg) can be substituted Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Management of PID after IUD Inpatient to Outpatient Treatment After 24 to 48 hours of clinical improvement, transition to: Cefotetan or Cefotxitin plus Doxycycline Doxycycline 100 mg orally BID to complete 14 days of therapy Clindamycin plus Gentamicin Clindamycin 450 mg orally 4 times a day OR Doxycycline 100 mg orally BID to complete 14 days of therapy When TOA is present Clindamycin 450 mg po QID or Metronidazole 500 mg BID to complete 14 days

Management of an STI with IUD in place (not PID)

Management of STI with IUD in place If woman test positive for chlamydia or gonorrhea Ok to keep IUD in place Treat according to CDC treatment guidelines Partner needs treatment Condom use Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Treatment for Chlamydial Infection Recommended Regimens Azithromycin 1 g orally, x 1 OR Doxycycline 100 mg orally BID x 7 days Alternative Regimens Erythromycin base 500 mg orally QID x 7 days OR Erythromycin ethylsuccinate 800 mg orally QID x 7 days OR Levofloxacin 500 mg orally QD x 7 days OR Ofloxacin 300 mg orally BID x 7 days Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Treatment for Gonococcal Infection Recommended Regimens Ceftriaxone 250 mg IM x 1 PLUS Azithromycin 1 g orally x 1 Alternative Regimens (if ceftriaxone is not available) Cefixime 400 mg orally x 1 PLUS Azithromycin 1 g orally x 1 Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(No. RR-3): 1-137.

Consider these scenarios:

Case 1 21 year old woman calls your office 24 hour after IUD placement with cramping and spotting. No fever, no foul smelling discharge: - Reassure that cramping can occur immediately after placement and last for a few days - Ibuprofen or Naproxen PRN pain - Warning symptoms of infection

Case 2 33 year old woman calls your office 2 weeks after IUD placement with low grade fever and severe lower abdominal pain - Prompt evaluation to diagnose PID - Physical examination, possible lab evaluation - If signs/ symptoms of PID prompt treatment

Useful tools Mobile Applications by the CDC Available for ios and Android www.cdc.gov/std/tg2015/default.htm www.cdc.gov/reproductivehealth/contraception/contraception_guidance.htm

Program Reminders Fax Master Z-CAN ID lists to 787-767-7781 Send Supply Re-order forms and Patient Encounter forms to zcan@cdcfoundation.org Next webinar: Wednesday, 2/1 @ 6pm